Breast Matrices rebound and grow modestly as AbbVie’s competitors take over market share. Biosynthetic and hybrid xenograft hernia matrices continue to drive growth in Hernia Matrices.

The US Surgical Matrices Market resumed its pre-pandemic trends, gaining +3.2% YoY according to SmartTRAK Financial Dashboard. AbbVie* and Becton Dickinson* (BD) remained in first and second positions, respectively, in the Q422 Surgical Matrices market. AbbVie held on to its leadership despite  a -4.4% YoY decline, while BD gained +6.1% YoY.

Among the many topics covered in detail in our comprehensive Q422 US Surgical Matrices Market Recap* are:

SmartTRAK reviews recent trends in hernia matrices and their potential impact on the US Hernia Matrices Market, which is projected to reach $1.06B in 2023 according to SmartTRAK.

Incisional hernia procedures reached a peak in the mid-2000s, with a gradual decline as surgeons performed fewer abdominal procedures and researchers investigated new techniques for closure. While improved stitching for closure has had mixed results, surgeons are trying other new approaches to reduce incisional hernias such as MSI’s DuraMesh* and Deep Blue Medical’s T-line mesh* which are being used prophylactically.

In this Market Outlook article, we cover in detail:

• Synthetic Matrices Poised for Slow Down
• Alternatives to Synthetic Matrices Gaining Favor
  • Xenograft Matrices
  • Resorbable Meshes
  • Reinforced Xenograft Matrices
• Expert Analysis and Conclusions

Biosynthetic hernia matrices continue their ascent and Xenograft hernia matrices grow, thanks to TELA Bio.

As elective surgical procedures settle into pre-pandemic levels, the US Surgical Matrices Market resumed trends that had begun prior to Q322, gaining +2.4% YoY according to SmartTRAK Financial Dashboard. AbbVie* and Becton Dickinson* (BD) have been trading share positions in the last few quarters and now once again AbbVie has first place in the Q322 Surgical Matrices market despite of a -5.4% YoY decline, with BD In second place.

Among the many topics covered in detail in our comprehensive Q322 US Surgical Matrices Market Recap* are:

Surgeons are concerned about the cost of breast matrices in an increasingly restrictive environment, but alternatives may be on the horizon according to key discussions at the 2022 Plastic Surgery: The Meeting.

Breast matrices are used to cover breast implants in breast reconstruction and cosmetic breast surgeries. The matrices have become in effect standard of care in these surgeries, though they do not have FDA-approved indications for breast reconstruction or cosmetic breast surgeries. Moreover, the FDA has in recent years, issued warning letters and communications related to breast matrices. In 2015, the FDA issued warning letters reminding several companies that they did not ...

To read the complete "Trends in ADM Use from ASPS 2022" article by Doug Devens, SmartTRAK's Product Director/Sr. Analyst - Wound, in which  he shares observations from the ASPS sessions and the potential implications for the Breast Matrices Market, just click the following link.

Surgical matrices revenue is flat while procedure volumes level out

With elective procedures in the United States mostly back at pre-pandemic levels, the US Surgical Matrices Market returned to what had been normal growth according to SmartTRAK Financial Dashboard. Becton Dickinson* (BD) grew to a 26.9% share, while AbbVie* slipped to second place.

Among the many topics covered in detail in our comprehensive Q222 US Surgical Matrices Market Recap* are:

Surgical matrices procedures appear back to near pre-pandemic levels, with revenues on the rise

With elective procedures in the United States mostly back at pre-pandemic levels, the US Surgical Matrices Market returned to what had been normal growth in Q122, gaining +5.7% YoY according to SmartTRAK Financial Dashboard. AbbVie* continued to lead the Surgical Matrices Market, though it was approximately flat, while Becton Dickinson* (BD) grew strongly.

Among the many topics covered in detail in our comprehensive Q122 US Surgical Matrices Market Recap* are:

SmartTRAK investigates recent trends in hernia repair clinical trials and how these trends relate to competition in the hernia repair market. Using a new SmartTRAK tool to analyze data in clinicaltrials.gov, SmartTRAK describes shifting trends in hernia repair research with company-sponsored studies and randomized controlled trials (RCTs)

SmartTRAK examines recent trends in breast implants and discusses their future impact on breast matrices.

Breast matrices, whether acellular dermal matrices (ADMs) or biosynthetics, have enabled improved outcomes in implant-based breast reconstruction and have contributed, in large part, to the revival of the prepectoral breast reconstruction technique. As the number of breast implant procedures has grown, so has the use of breast matrices. However, SmartTRAK believes the side effects and health consequences now associated with breast implants, while rare, will negatively impact breast implant usage and thus reduce the growth rate of breast matrices in 2022 and beyond.

In this informative Outlook article by Doug Devens, SmartTRAK's Product Director and Senior Editor, Wound, Doug covers:

• The Relationship between Breast Surgery and ADM Usage
• Trends in Implant Usage
• Recent Concerns that May Affect Breast Implant Usage
• The Future Outlook for 2022 and Beyond

Procedures using surgical matrices continued their recovery and companies have resumed investing, with revenues surpassing their Q419 levels. 

As the pandemic wanes and procedures are again being scheduled, the US Surgical Matrices market grew strongly in Q421, gaining +12.7% YoY according to the SmartTRAK Financial Dashboard. AbbVie continued to lead the Surgical Matrices market, with Becton Dickinson also growing well ...

Among the many topics covered in detail in our comprehensive Q421 US Surgical Matrices Market Recap* are:

SmartTRAK highlights current and emerging trends in hernia outcomes research presented at the European Hernia Society – Americas Hernia Society Joint Congress held in Copenhagen.

by Doug Devens - Sr Analyst, Biosurgery, IT Product Director

Changes in hernia regulations and evolving views on how to study the performance of hernia matrices have fueled a growing interest among hernia researchers in using different methods and data sources to measure outcomes associated with these devices. In this article, SmartTRAK highlights current and emerging trends in hernia outcomes research presented at the European Hernia Society – Americas Hernia Society Joint Congress (Hernia2021), in Copenhagen, including the increasing use of registries and their relative advantages and disadvantages compared to the gold standard randomized controlled trial (RCT). ­